search
Back to results

Treatment of HFpEF With Nitrate Supplement

Primary Purpose

Heart Failure With Normal Ejection Fraction

Status
Completed
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
Active lozenge
Placebo
Sponsored by
MaineHealth
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Heart Failure With Normal Ejection Fraction focused on measuring Heart failure, HFpEF, Nitrate supplement

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Diagnosis of HFpEF, defined as:

    • symptomatic with one of more of the following: orthopnea, paroxysmal nocturnal dyspnea, lower-extremity edema, dyspnea on exertion; AND
    • ejection fraction >50%
    • ratio of early mitral inflow velocity to septal tissue dopler velocity >8; AND
    • one or more of the following: left atrium measurement >34 mL/m2, elevated N-terminal pro-brain natriuretic peptide level within the past 12 months, long term loop diuretic use for control of symptoms or elevated filling pressures on prior cardiac catheterization
  2. Stable medical therapy, defined as: no change in cardiac medications within 30 days
  3. Willing to comply with the protocol and provide written informed consent

Exclusion Criteria:

  1. Non-cardiac condition causing limitation of exercise tolerance
  2. Acute coronary syndrome, myocardial infarction or cardiac revascularization within 60 days
  3. Clinically significant valvular disease, defined as moderate-severe or severe stenosis or insufficiency
  4. Significant ischemia seen on stress testing within the past 12 months that was not revascularized
  5. Subject has taken and investigational medication within the past 30 days
  6. History of allergy to beets
  7. Systolic blood pressure of <100 at screening
  8. Significant medical condition that would interfere with treatment, safety or compliance with the protocol

Sites / Locations

  • Penobscot Bay Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Active lozenge first

Placebo lozenge first

Arm Description

Subject will take active lozenge (Vitamin C, Vitamin B12, Nitric Oxide Blend, L-citrulline, Sodium Nitrite) for one week, perform cardiac testing then take placebo lozenge for one week and perform cardiac testing.

Subject will take placebo lozenge for one week, perform cardiac testing then take active lozenge (Vitamin C, Vitamin B12, Nitric Oxide Blend, L-citrulline, Sodium Nitrite) for one week and perform cardiac testing.

Outcomes

Primary Outcome Measures

Time on Treadmill
change in total time traveled on treadmill
Metabolic Equivalents
change in metabolic equivalents on treadmill
E/E Prime
change in E/E prime on exercise echo (E/E prime is a ratio between early mitral inflow velocity and mitral annular early diastolic velocity in order to measure diastolic dysfunction)
Estimated Right Ventricular Systolic Pressure
change in estimated right ventricular systolic pressure on echo

Secondary Outcome Measures

Full Information

First Posted
September 18, 2017
Last Updated
September 16, 2021
Sponsor
MaineHealth
Collaborators
HumanN
search

1. Study Identification

Unique Protocol Identification Number
NCT03289481
Brief Title
Treatment of HFpEF With Nitrate Supplement
Official Title
Treatment of HFpEF With Nitrate Supplement: A Double-blind, Placebo Controlled Trial Including Patients With Atrial Fibrillation
Study Type
Interventional

2. Study Status

Record Verification Date
September 2021
Overall Recruitment Status
Completed
Study Start Date
June 29, 2017 (Actual)
Primary Completion Date
August 22, 2018 (Actual)
Study Completion Date
August 22, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
MaineHealth
Collaborators
HumanN

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of this project is to determine if Neo40, a nitric oxide generating lozenge, when consumed twice daily by subjects with HFpEF, will increase exercise tolerance, decrease symptoms and improve quality of life for patients.
Detailed Description
Heart failure (HF) is the most common principal diagnosis for hospital admission in patients over 65 years old. There are two types of HF, those with reduced ejection fraction (HFrEF) and those with preserved ejection fraction (HFpEF). Approximately half of patients with the clinical syndrome of HF have preserved systolic function. HEpEF is becoming more prevalent with aging of the population and obesity. There are only two class I recommendations for the treatment of HFpEF, which are controlling blood pressure and the use of diuretics to relieve symptoms. Exercise training is another approach to improving symptoms, however it may be poorly tolerated. Nitrate supplement in the form of concentrated beetroot juice was recently shown to improve exercise tolerance in patients with HFpEF. (1) Beetroot juice contains high concentration of nitrate (NO3). This is metabolized to nitrite (NO2). It enters the blood stream, where it is further reduced to nitric oxide (NO) resulting in intense vasodilation. Patients with diastolic dysfunction are often asymptomatic at rest but complain of dyspnea with exertion. Increase in heart rate with exercise causes reduced diastolic filling time and increases left sided filling pressure. Borloug, et al demonstrated this with right heart catheterization and supine exercise in patients with diastolic dysfunction. Infusion of NO2 resulted in decreased filling pressures and increased cardiac output. (2) Neo40 is a new product made from concentrated beetroot juice in the form of a lozenge designed to dissolve on the tongue. NO3 supplement causes vasodilatation only in the setting of hypoxia and acidosis resulting in targeted vasodilatation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Failure With Normal Ejection Fraction
Keywords
Heart failure, HFpEF, Nitrate supplement

7. Study Design

Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Crossover Assignment
Model Description
Double-blind, placebo controlled crossover study
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Masking will be done by the pharmacy. Active and placebo lozenges will look identical.
Allocation
Randomized
Enrollment
13 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Active lozenge first
Arm Type
Active Comparator
Arm Description
Subject will take active lozenge (Vitamin C, Vitamin B12, Nitric Oxide Blend, L-citrulline, Sodium Nitrite) for one week, perform cardiac testing then take placebo lozenge for one week and perform cardiac testing.
Arm Title
Placebo lozenge first
Arm Type
Active Comparator
Arm Description
Subject will take placebo lozenge for one week, perform cardiac testing then take active lozenge (Vitamin C, Vitamin B12, Nitric Oxide Blend, L-citrulline, Sodium Nitrite) for one week and perform cardiac testing.
Intervention Type
Dietary Supplement
Intervention Name(s)
Active lozenge
Intervention Description
nitric oxide generating lozenge
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
placebo tablet
Primary Outcome Measure Information:
Title
Time on Treadmill
Description
change in total time traveled on treadmill
Time Frame
after one week of active lozenges compared to one week of placebo lozenges
Title
Metabolic Equivalents
Description
change in metabolic equivalents on treadmill
Time Frame
after one week of active lozenges compared to one week of placebo lozenges
Title
E/E Prime
Description
change in E/E prime on exercise echo (E/E prime is a ratio between early mitral inflow velocity and mitral annular early diastolic velocity in order to measure diastolic dysfunction)
Time Frame
after one week of active lozenges compared to one week of placebo lozenges
Title
Estimated Right Ventricular Systolic Pressure
Description
change in estimated right ventricular systolic pressure on echo
Time Frame
after one week of active lozenges compared to one week of placebo lozenges

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of HFpEF, defined as: symptomatic with one of more of the following: orthopnea, paroxysmal nocturnal dyspnea, lower-extremity edema, dyspnea on exertion; AND ejection fraction >50% ratio of early mitral inflow velocity to septal tissue dopler velocity >8; AND one or more of the following: left atrium measurement >34 mL/m2, elevated N-terminal pro-brain natriuretic peptide level within the past 12 months, long term loop diuretic use for control of symptoms or elevated filling pressures on prior cardiac catheterization Stable medical therapy, defined as: no change in cardiac medications within 30 days Willing to comply with the protocol and provide written informed consent Exclusion Criteria: Non-cardiac condition causing limitation of exercise tolerance Acute coronary syndrome, myocardial infarction or cardiac revascularization within 60 days Clinically significant valvular disease, defined as moderate-severe or severe stenosis or insufficiency Significant ischemia seen on stress testing within the past 12 months that was not revascularized Subject has taken and investigational medication within the past 30 days History of allergy to beets Systolic blood pressure of <100 at screening Significant medical condition that would interfere with treatment, safety or compliance with the protocol
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ralph Hamill, MD
Organizational Affiliation
MaineHealth
Official's Role
Principal Investigator
Facility Information:
Facility Name
Penobscot Bay Medical Center
City
Rockport
State/Province
Maine
ZIP/Postal Code
04856
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
26874390
Citation
Eggebeen J, Kim-Shapiro DB, Haykowsky M, Morgan TM, Basu S, Brubaker P, Rejeski J, Kitzman DW. One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction. JACC Heart Fail. 2016 Jun;4(6):428-37. doi: 10.1016/j.jchf.2015.12.013. Epub 2016 Feb 10.
Results Reference
background
PubMed Identifier
26449137
Citation
Borlaug BA, Koepp KE, Melenovsky V. Sodium Nitrite Improves Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2015 Oct 13;66(15):1672-82. doi: 10.1016/j.jacc.2015.07.067.
Results Reference
background

Learn more about this trial

Treatment of HFpEF With Nitrate Supplement

We'll reach out to this number within 24 hrs